NSE: SAKAR · ISIN INE732S01012
Sakar Healthcare Limited stock analysis
Sakar Healthcare Limited ranks #289 in the TickerSutra evidence-ranked universe with a score of 67/100 and 95% data confidence. The latest captured fundamentals show ROCE of 12.4%, quarterly sales growth of 38.4% and quarterly profit growth of 120.1%.Watchlist candidate
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- Low debt/equity of 0.22×
- 23.6% three-year sales CAGR
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- Valuation is above 40× earnings
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹128cr | ₹29cr | ₹15cr | 23.0% |
| 2023 | ₹133cr | ₹33cr | ₹13cr | 25.0% |
| 2024 | ₹153cr | ₹38cr | ₹12cr | 25.0% |
| 2025 | ₹178cr | ₹50cr | ₹18cr | 28.0% |
| 2026 | ₹251cr | ₹69cr | ₹30cr | 27.0% |
| TTM | ₹272cr | ₹77cr | ₹36cr | 28.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
Sakar Healthcare Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
RoutineChange in Directors/KMP/SMP/Auditor/RTANSE · 22 Sept 2026 · Structured filingSAKAR HEALTHCARE LIMITED has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA
SAKAR HEALTHCARE LIMITED has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA
Open original XBRL sourceSakar Healthcare Limited has informed the Exchange regarding Appointment of M/s. Kashyap R. Mehta & Partners as Secretarial Auditors of the Company for the term of 5 years w.e.f. September 22, 2026.
RoutineShareholders meetingNSE · 22 Sept 2026Sakar Healthcare Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 22, 2026. Further, the company has informed the Exchange regarding voting results.
RoutineShareholders meetingNSE · 22 Sept 2026Sakar Healthcare Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 22, 2026
MANAGEMENT COMMENTARY
Signals from filed documents
Export revenues also witnessed healthy year -on-year growth, reflecting our expanding global footprint and increasing acceptance of products in international markets. The improvement in profitability reflects a combination of better product mix, higher operating leverage, increasing contribution from oncology products, and continued execution discipline across the organization. As we look ahead, we believe the opport
The Bavla oncology facility has been designed with significant growth potential and we believe it can support revenues of INR800 crores to INR1,000 crores at optimal utilization over the next 4 to 5 years without requiring any major incremental capital expenditure. Given the current level of utilization, we continue to see substantial headroom for growth, operating leverage, and margin expansion as product registrati
The first quarter of FY27 has been encouraging for Sakar Healthcare, both operationally and financially. Over the last few years, we have built an oncology business with a clear objective to establish a strong presence in global markets through differentiated products, regulatory-driven market access, and long -term commercial partnerships. As we move forward, we see Sakar evolving into a predominantly oncology-led e
Our oncology division continued to demonstrate strong momentum during the quarter, making a meaningful contribution to the company's overall performance. Export revenues also witnessed healthy year -on-year growth, reflecting our expanding global footprint and increasing acceptance of products in international markets. The improvement in profitability reflects a combination of better product mix, higher operating lev
What is particularly important is that every approval expands our footprint into new markets and creates additional opportunities for future product launches. Today, our regulatory pipeline i s wider than it has been ever, providing us with increased visibility across regulated as well as emerging markets. At the same time, our product portfolio continues to deepen.
Our collaboration with Zydus Lifesciences during the quarter further reinforces this trend and marks our 40th global anti -cancer product agreement. We also continue to strengthen the economics of our business through backward integration. With 21 oncology APIs developed in-house, including 16 APIs supported by written confirmations along with CEP approvals and ongoing CEP applications, we are steadily improving cont
As we move forward, we see Sakar evolving into a predominantly oncology-led export franchise. Our efforts across product development, dossiers, marketing authorization, technology transfers, and API integration are all aligned towards building a larger and more sustainable oncology export business over the coming years. What we are witnessing today is a steady increase in opportunities across all three areas.
Because that is the again a generic product going to the emerging market. So, once you grow by 8% to 9% also there are certain competition, there are certain price erosion so everything factored in we can grow around 7% to 8% as per market trend with the non-oncology. But with the oncology the thing is that where we are putting in more of focus and more of inputs have already gone in.
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…